A Phase 2 interventional study of Abemaciclib and Loperamide in Breast Cancer, Hormone Receptor Positive Tumor and Early-Stage Breast Carcinoma, sponsored by Eli Lilly and Company. Completed at 66 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 27 in phase 2, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 27th largest by enrollment of the 80 interventional ones that give a count, is one of 2 that started in 2015, is one of 41 in phase 2, and was the 53rd registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole
Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.
Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole
Anastrozole (1 mg) is given orally QD for 2 weeks. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks.
Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole
Administered orally
Also known as: LY2835219
Administered orally
Administered orally
Percent Change From Baseline to 2 Weeks in Ki67 Expression
Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.
Time frame: Baseline, 2 Weeks
Percentage of Participants With Pathologic Complete Response (pCR)
pCR is defined as absence of invasive cancer in the breast and sampled regional lymph nodes.
Time frame: From Start of Treatment Up to 16 Weeks
Percentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response
Clinical objective response is defined as the percentage of participants with the best overall response rate (ORR) with a best OR of CR or PR, according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1. ORR is recorded from the start of the study treatment until the earliest of objective progression or start of new anticancer therapy. A responder depends on target and non-target disease and the appearance of new lesions. CR is defined as the disappearance of all non-target lesions. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. All lymph nodes are non-pathological or normal in size (\<10mm short axis). Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, a relative increase of 20%, the sum must also demonstrate an absolute increase of 5 mm.
Time frame: From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)
Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response
Radiological response is the percentage of participants with CR or, PR according to RECIST v.1.1. A responder is defined as any participant who exhibits a CR or PR. CR is the disappearance of all target lesions. PR is a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD is 20% increase in the sum of diameters of target lesions taking as reference the smallest sum and the appearance of 1 or more new lesions.
Time frame: From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)
Change From Baseline to Week 2 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, emotional, cognitive, or social functioning), global health status and symptom scales of fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.
Time frame: Baseline, 2 Weeks
Pharmacokinetics (PK): Apparent Clearance of Abemaciclib
Abemaciclib apparent clearance (CL/F) was calculated by population nonlinear mixed effects modeling (NONMEM) using all available data spanning cycles 1 and cycles 3-5.
Time frame: Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose
PK: Apparent Volume of Distribution of Abemaciclib
Abemaciclib apparent volume of distribution was calculated by population NONMEM using all available data spanning cycles 1 and cycles 3-5.
Time frame: Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose
| Milestone | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Started | 74 | 76 | 74 |
| Received at least one dose of study drug | 74 | 75 | 74 |
| Completed | 72 | 71 | 74 |
| Not completed | 2 | 5 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 |
| Withdrew: Never treated | 0 | 1 | 0 |
| Milestone | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Started | 217 | 0 | 0 |
| Received at least one dose of study drug | 217 | 0 | 0 |
| Progressive disease | 5 | 0 | 0 |
| Completed | 190 | 0 | 0 |
| Not completed | 27 | 0 | 0 |
| Withdrew: Adverse event | 15 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 | 0 |
| Milestone | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Started | 42 | 0 | 0 |
| Completed | 40 | 0 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.
| Percent Change | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Percent Change From Baseline to 2 Weeks in Ki67 Expression | -92.86 (-94.82 to -90.16) | -90.52 (-93.12 to -86.93) | -62.78 (-72.99 to -48.71) |
pCR is defined as absence of invasive cancer in the breast and sampled regional lymph nodes.
| percentage of participants | Abemaciclib + Anastrozole |
|---|---|
| Percentage of Participants With Pathologic Complete Response (pCR) | 3.7 |
Clinical objective response is defined as the percentage of participants with the best overall response rate (ORR) with a best OR of CR or PR, according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1. ORR is recorded from the start of the study treatment until the earliest of objective progression or start of new anticancer therapy. A responder depends on target and non-target disease and the appearance of new lesions. CR is defined as the disappearance of all non-target lesions. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. All lymph nodes are non-pathological or normal in size (\<10mm short axis). Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, a relative increase of 20%, the sum must also demonstrate an absolute increase of 5 mm.
| percentage of participants | Abemaciclib + Anastrozole |
|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response | 53.6 |
Radiological response is the percentage of participants with CR or, PR according to RECIST v.1.1. A responder is defined as any participant who exhibits a CR or PR. CR is the disappearance of all target lesions. PR is a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD is 20% increase in the sum of diameters of target lesions taking as reference the smallest sum and the appearance of 1 or more new lesions.
| percentage of participants | Abemaciclib + Anastrozole |
|---|---|
| Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response | 46.4 |
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, emotional, cognitive, or social functioning), global health status and symptom scales of fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.
| units on a scale | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Global Health Status | -9.5 ± 17.9 | -7.6 ± 18.1 | -2.3 ± 13.4 |
| Physical Functioning | -3.2 ± 10.2 | -5.5 ± 12.6 | -0.3 ± 7.5 |
| Role Functioning | -11.3 ± 23.7 | -11.4 ± 24.0 | -2.2 ± 17.4 |
| Emotional | 5.4 ± 17.1 | 3.5 ± 21.4 | 1.3 ± 14.0 |
| Cognitive | 0.5 ± 12.4 | -2.0 ± 15.6 | -1.4 ± 11.0 |
| Social Functioning | -8.3 ± 18.8 | -3.5 ± 16.7 | -0.7 ± 12.6 |
| Fatigue | 13.6 ± 23.2 | 13.9 ± 22.6 | 4.0 ± 12.8 |
| Nausea/Vomiting | 11.8 ± 17.7 | 9.6 ± 12.4 | 2.7 ± 7.4 |
| Pain | 4.8 ± 19.9 | 3.5 ± 19.3 | 2.9 ± 16.7 |
| Dyspnea | 1.1 ± 19.1 | 0.5 ± 19.8 | -1.0 ± 12.7 |
| Insomnia | -1.1 ± 19.1 | 0.5 ± 29.5 | -1.9 ± 22.1 |
| Appetite Loss | 16.9 ± 28.3 | 16.9 ± 27.5 | 1.9 ± 15.0 |
| Constipation | 22.4 ± 31.5 | 16.9 ± 31.2 | 1.9 ± 15.0 |
| Diarrhea | 18.3 ± 29.4 | 27.8 ± 25.9 | 0.0 ± 15.1 |
| Financial Impact | -2.8 ± 19.7 | 2.0 ± 18.4 | 0.0 ± 11.4 |
Abemaciclib apparent clearance (CL/F) was calculated by population nonlinear mixed effects modeling (NONMEM) using all available data spanning cycles 1 and cycles 3-5.
| Liters/hour (L/h) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| Pharmacokinetics (PK): Apparent Clearance of Abemaciclib | 24.0 ± 32 | 19.1 ± 55 | 24.4 ± 61 |
Abemaciclib apparent volume of distribution was calculated by population NONMEM using all available data spanning cycles 1 and cycles 3-5.
| Liters (L) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole |
|---|---|---|---|
| PK: Apparent Volume of Distribution of Abemaciclib | 941 ± 53 | 720 ± 58 | 758 ± 49 |
Collected over Up to 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib + Anastrozole Cycle 1 | — | 1/74 (1.4%) | 62/74 (83.8%) |
| Abemaciclib Cycle 1 | — | 1/75 (1.3%) | 58/75 (77.3%) |
| Anastrozole Cycle 1 | — | 0/74 (0%) | 17/74 (23%) |
| Abemaciclib + Anastrozole Cycle 2 and Beyond | — | 16/217 (7.4%) | 189/217 (87.1%) |
| Event | Abemaciclib + Anastrozole Cycle 1 | Abemaciclib Cycle 1 | Anastrozole Cycle 1 | Abemaciclib + Anastrozole Cycle 2 and Beyond |
|---|---|---|---|---|
| FractureInjury, poisoning and procedural complications | 0/74 | 0/75 | 0/74 | 3/217 |
| Abdominal painGastrointestinal disorders | 1/74 | 0/75 | 0/74 | 1/217 |
| Alanine aminotransferase increasedInvestigations | 1/74 | 0/75 | 0/74 | 0/217 |
| Aspartate aminotransferase increasedInvestigations | 1/74 | 0/75 | 0/74 | 0/217 |
| Decreased appetiteMetabolism and nutrition disorders | 0/74 | 1/75 | 0/74 | 0/217 |
| MastitisInfections and infestations | 0/74 | 0/75 | 0/74 | 2/217 |
| Blood creatinine increasedInvestigations | 0/74 | 0/75 | 0/74 | 2/217 |
| NeutropeniaBlood and lymphatic system disorders | 0/74 | 0/75 | 0/74 | 1/217 |
| Acute coronary syndromeCardiac disorders | 0/74 | 0/75 | 0/74 | 1/217 |
| Angina pectorisCardiac disorders | 0/74 | 0/75 | 0/74 | 1/217 |
| Event | Abemaciclib + Anastrozole Cycle 1 | Abemaciclib Cycle 1 | Anastrozole Cycle 1 | Abemaciclib + Anastrozole Cycle 2 and Beyond |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/74 | 29/75 | 2/74 | 101/217 |
| ConstipationGastrointestinal disorders | 27/74 | 26/75 | 5/74 | 50/217 |
| NauseaGastrointestinal disorders | 19/74 | 15/75 | 2/74 | 67/217 |
| FatigueGeneral disorders | 19/74 | 17/75 | 3/74 | 62/217 |
| NeutropeniaBlood and lymphatic system disorders | 2/74 | 1/75 | 0/74 | 45/217 |
| Abdominal painGastrointestinal disorders | 13/74 | 7/75 | 2/74 | 30/217 |
| Decreased appetiteMetabolism and nutrition disorders | 5/74 | 13/75 | 0/74 | 33/217 |
| AnaemiaBlood and lymphatic system disorders | 0/74 | 3/75 | 0/74 | 27/217 |
| Alanine aminotransferase increasedInvestigations | 4/74 | 1/75 | 0/74 | 26/217 |
| VomitingGastrointestinal disorders | 5/74 | 1/75 | 0/74 | 25/217 |
| Age, Continuous(years) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| Mean | 63.9 ± 8.4 | 63.8 ± 7.9 | 64.9 ± 8.4 | 64.2 ± 8.2 |
| Sex: Female, Male(Participants) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| Female | 74 | 76 | 74 | 224 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 5 | 19 |
| Not Hispanic or Latino | 61 | 61 | 60 | 182 |
| Unknown or Not Reported | 7 | 7 | 9 | 23 |
| Race (NIH/OMB)(Participants) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 16 | 16 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 5 | 1 | 2 | 8 |
| White | 55 | 57 | 55 | 167 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| Canada | 0 | 3 | 1 | 4 |
| Austria | 10 | 4 | 12 | 26 |
| Netherlands | 1 | 0 | 2 | 3 |
| Belgium | 5 | 2 | 4 | 11 |
| United States | 26 | 28 | 26 | 80 |
| Taiwan | 5 | 7 | 11 | 23 |
| South Korea | 5 | 7 | 2 | 14 |
| Italy | 4 | 3 | 4 | 11 |
| Germany | 5 | 6 | 4 | 15 |
| Spain | 13 | 16 | 8 | 37 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| 0 (Fully Active) | 69 | 70 | 63 | 202 |
| 1 (Restricted, able to do light sedentary work) | 5 | 5 | 10 | 20 |
| Unreported | 0 | 1 | 1 | 2 |
| Ki67 at Baseline(Percent Cells Positive) | Abemaciclib + Anastrozole | Abemaciclib | Anastrozole | Total |
|---|---|---|---|---|
| Mean | 27.24 ± 13.56 | 27.88 ± 12.13 | 26.86 ± 12.32 | 27.33 ± 12.63 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Aug 2015, a primary completion of Aug 2016 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 1 year 5 months after primary completion. A results delay was requested in Dec 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Anastrozole